trial

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

NCTId NCT00538642
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 24 (actual)
Sponsored by The University of Texas Health Science Center at San Antonio
Primary completion 2011-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2007-08
Primary completion
2011-04
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Ziprasidone

Sponsors

The University of Texas Health Science Center at San AntonioLead Sponsor

Investigators

1
ALEXANDER L MILLER, MDPrincipal Investigator

Sites

1 total
San Antonio, United States

Facts & assertions

4 sourced
Enrollment
24
Phase
NA
Primary Completion Date
2011-04
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
lead_sponsor
The University of Texas Health Science Center at San Antonio
company
indication
Bipolar Disorder
indication
Schizoaffective Disorder
indication
Diabetes Mellitus
indication
investigator
ALEXANDER L MILLER, MD
person